Aspirin as adjuvant therapy for stage III colon cancer: Standard of care?

Menée sur des échantillons tumoraux prélevés sur 999 patients ayant subi une résection d'une tumeur du côlon entre 2002 et 2008, ainsi qu'à partir d'une base de données de prescriptions, cette étude évalue les bénéfices, en termes de survie globale, de faibles doses d'aspirine en fonction de l'expression du complexe majeur d'histocompatibilité de classe I ou du gène PTGS2 et de la présence de mutations du gène PI3KCA

Résumé en anglais

When one sees a patient newly diagnosed as having cancer, after finishing the initial discussion and treatment plan, it is almost inevitable that the patient or a family member will inquire, “What else should he [or she] do?” The implication is that, aside from whatever benefits orthodox therapy—surgery, chemotherapy, radiotherapy—may confer, there are also additional benefits to be gained from lifestyle or behavioral changes, such as diet. I suppose that such beliefs stem from the remarkable benefits in this arena that one can see in cardiovascular disease, where diet, physical activity, and aspirin use are all routine, well accepted, and evidence-based parts of the post–myocardial infarction management landscape. It is no wonder that a patient with breast, colon, prostate, or lung cancer should not anticipate that similar recommendations would be forthcoming...